Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial

被引：0
|
作者：
Wang, S. [1 ]
Hong, R. [2 ]
Xu, F. [2 ]
Xia, W. [2 ]
Teng, Y. [3 ]
Ouyang, Q. [4 ]
Yuan, Z. [2 ]
Jiang, K. [2 ]
Lin, Y. [5 ]
Liu, X. [6 ]
Chen, Q. [7 ]
Wu, X. [8 ]
Shi, Y. [2 ]
Huang, J. [2 ]
An, X. [2 ]
Xue, C. [2 ]
Bi, X. [2 ]
Zheng, Q. [2 ]
Chen, M. [2 ]
Li, H. [9 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[3] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Liaoning, Peoples R China
[4] Hunan Canc Hosp, Dept Breast Canc Med Oncol, Changsha, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Surg, Guangzhou, Peoples R China
[6] Ningxia Med Univ, Gen Hosp, Dept Med Oncol, Yinchuan, Ningxia, Peoples R China
[7] Guangdong Prov Chinese Med Hosp, Dept Breast, Guangzhou, Peoples R China
[8] Hubei Canc Hosp, Dept Breast, Wuhan, Peoples R China
[9] Sichuan Canc Hosp, Dept Breast Surg, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371P
引用
收藏
页码：S374 / S374
页数：1
相关论文
共 50 条
  • [1] Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial
    Hong, Ruo-Xi
    Xu, Fei
    Xia, Wen
    Teng, Yue-E
    Ouyang, Qu-Chang
    Zheng, Qiu-Fan
    Yuan, Zhong-Yu
    Chen, Dong-Shao
    Jiang, Kui-Kui
    Lin, Ying
    Dai, Zhen
    Liu, Xin-Lan
    Chen, Qian-Jun
    Wu, Xin-Hong
    Shi, Yan-Xia
    Huang, Jia-Jia
    An, Xin
    Xue, Cong
    Bi, Xi-Wen
    Chen, Mei-Ting
    Li, Hui
    Yao, He-Rui
    Zou, Guo-Rong
    Huang, Heng
    Zhang, Jing-Min
    Wang, Shu-Sen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11)
  • [2] Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer
    Abdelmaksoud, Bader A.
    Toam, Mostafa M.
    Fayed, Alaa A.
    BREAST CANCER MANAGEMENT, 2019, 8 (03)
  • [3] Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Schwartzberg, Lee S.
    Wang, Grace
    Somer, Bradley G.
    Blakely, L. Johnetta
    Wheeler, Benton M.
    Walker, Mark S.
    Stepanski, Edward J.
    Houts, Arthur C.
    CLINICAL BREAST CANCER, 2014, 14 (01) : 13 - 19
  • [4] Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
    Alvarado-Miranda, Alberto
    Lara-Medina, Fernando Ulises
    Munoz-Montano, Wendy R.
    Zinser-Sierra, Juan W.
    Galeana, Paula Anel Cabrera
    Garza, Cynthia Villarreal
    Benitez, Daniel Sanchez
    Rodriguez, Jesus Alberto Limon
    Salinas, Claudia Haydee Arce
    Guijosa, Alberto
    Arrieta, Oscar
    CURRENT ONCOLOGY, 2023, 30 (07) : 6097 - 6110
  • [5] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    FUTURE ONCOLOGY, 2023, : 727 - 736
  • [6] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [7] A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer
    Ardavanis-loukeris, Gerasimos
    Kokkali, Stefania
    Perdikari, Konstantina
    Karatrasoglou, Eleni
    Talagani, Sofia
    Tzovaras, Alexandros
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2024, 44 (04) : 1559 - 1565
  • [8] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [9] Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
    Martin, Miguel
    Zielinski, Christoph
    Ruiz-Borrego, Manuel
    Carrasco, Eva
    Ciruelos, Eva M.
    Munoz, Montserrat
    Bermejo, Begona
    Margeli, Mireia
    Csoszi, Tibor
    Anton, Antonio
    Turner, Nicholas
    Casas, Maria, I
    Morales, Serafin
    Alba, Emilio
    Calvo, Lourdes
    De La Haba-Rodriguez, Juan
    Ramos, Manuel
    Murillo, Laura
    Santaballa, Ana
    Alonso-Romero, Jose L.
    Sanchez-Rovira, Pedro
    Corsaro, Massimo
    Huang, Xin
    Thallinger, Christiane
    Kahan, Zsuzsanna
    Gil-Gil, Miguel
    EUROPEAN JOURNAL OF CANCER, 2022, 168 : 12 - 24
  • [10] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
12345